IDYA stock analysis covers price trends, earnings, technicals, and 2026 forecast at $51.21. Analysts rate Buy amid oncology pipeline growth. Is IDYA stock a buy? Explore now.
Introduction
IDYA stock draws investor eyes as IDEAYA Biosciences advances cancer drugs like darovasertib for uveal melanoma.
This NASDAQ biotech firm targets precision oncology with promising trials underway.
Tech stocks face volatility in 2026 amid rate cuts, but biotech shines on trial data.
Latest Stock Price & Trend
As of last market close on March 3, 2026, IDYA stock price stands at $34.84.
It rose 2.9% that day, trading between $33.86 low and $35.90 high.
Over five days, shares gained amid insider buys; one-month trend shows sideways action near $35.
Three-month performance holds steady, up slightly year-to-date despite biotech swings.
Six-month trend leans bullish from $30 support, with 52-week high at $35.90 and low at $25.
Overall, the trend points bullish for investors, signaling trial momentum over market noise.
Technical Analysis
Support levels sit at $33.86, a recent low where buyers stepped in.
Resistance looms near $35.90 52-week high; breaks signal upside.
RSI reading hovers neutral at 50-60, avoiding overbought or oversold extremes—good for beginners as it flags momentum shifts.
MACD trend shows bullish crossover, hinting gains ahead; this matters as it spots trend reversals early.
50-day moving average at $34 aligns with 200-day at $32, forming a golden cross—bullish sign of sustained uptrend.
Trading volume spiked on insider news, confirming interest; higher volume validates price moves.
Analyst Ratings & Price Targets
Fourteen analysts rate IDYA stock a consensus Buy: 36% Strong Buy, 57% Buy, 7% Hold.
Average price target hits $51.21, with highs near $60 and lows at $45—implies 47% upside from $34.84.
No recent downgrades; firms like Piper Sandler stay bullish on darovasertib Phase 3 data.
This sentiment guides everyday investors toward growth potential in oncology.
Insider Activity
Director Stein bought $1.65 million in IDYA stock on March 2, 2026, at average prices near $35.
No major selling reported recently; this large buy signals management confidence.
Trends show insiders accumulating shares amid trial progress, implying optimism over caution.
Valuation Analysis
IDYA trades at trailing P/E of -25.35 due to no profits yet, common for clinical-stage biotech.
Forward P/E not applicable; price-to-sales N/A as pre-revenue, but pipeline eyes $3.2B peak sales.
Revenue growth awaits approvals; EPS growth tied to darovasertib success.
Free cash flow burns cash on R&D; strong cash position funds trials without heavy debt.
Compared to peers like Beam Therapeutics, IDYA appears undervalued on pipeline value versus market cap of $3.06B.
Recent Earnings & Catalysts
Latest quarterly results showed R&D progress, no revenue yet as trials ramp.
EPS missed on cash burn, but beat low expectations with trial enrollment.
Forward guidance highlights Phase 3 darovasertib trials and IDE397 combo data.
Catalysts include first Phase 1 patient in IDE034 trial and crizotinib synergy.
Earnings lifted IDYA stock 3% post-announcement on pipeline momentum.
Bullish Case
Darovasertib shows anti-tumor efficacy in metastatic uveal melanoma trials.
Two Phase 3 studies target registration, with $3.2B revenue upside.
Crizotinib combo boosts safety and results in precision oncology demand.
Operational advances like IDE034 enrollment add pipeline depth.
Bearish Case
Trial failures could tank shares; no revenue heightens burn risk.
Regulatory delays or IP issues loom in competitive oncology space.
Biotech peers like Zentalis face similar pipeline risks.
Economic slowdowns cut funding for speculative biotech.
Market Sentiment & Investor Psychology
Short interest low at under 5%, easing pressure.
Options skew to calls, like March 2026 $35 strikes up 58%.
Institutions hold steady; retail piles in on insider buys.
Sentiment tilts optimistic on trial news over value traps.
Short-Term Outlook
Technicals favor upside past $35 resistance on volume.
Insider buying and MACD support momentum next week.
Watch $33 support; expect volatility around trial updates.
Medium to Long-Term Outlook
Strong pipeline in oncology positions IDYA for approvals by 2027.
Industry growth in precision medicine aids competitive edge.
Healthy cash runway mitigates risks for long-term holders.
Accumulate on dips; hold for Phase 3 catalysts.
FAQ Section
Is IDYA stock a buy right now?
Yes, 14 analysts say Buy on pipeline strength, but weigh trial risks.
What is the IDYA stock price target?
Average $51.21, up 47% from current levels per Wall Street.
IDYA stock forecast for 2026?
Targets $51+ on darovasertib success; monitor Phase 3 data.
What are major risks for IDYA stock?
Trial flops, no revenue, regulatory hurdles top concerns.
IDYA earnings outlook?
Pre-revenue; growth tied to approvals and peak sales potential.
Suggestions
Compare with Opendoor stock
See our IDYA earnings deep dive.
Read our biotech sector valuation trends.
Conclusion
Hold or accumulate IDYA stock for long-term investors eyeing oncology growth, but watch trial risks closely. Analysts’ Buy rating and $51 target support upside against biotech volatility.
Disclaimer: This article is for informational purposes only and not financial advice.